The estimated Net Worth of Martin Javier San is at least $8.98 millió dollars as of 4 January 2024. Dr San owns over 8,303 units of Arrowhead Pharmaceuticals stock worth over $4,156,527 and over the last 4 years he sold ARWR stock worth over $4,149,579. In addition, he makes $673,571 as Chief Medical Officer at Arrowhead Pharmaceuticals.
Dr has made over 5 trades of the Arrowhead Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 8,303 units of ARWR stock worth $292,764 on 4 January 2024.
The largest trade he's ever made was selling 19,700 units of Arrowhead Pharmaceuticals stock on 20 November 2023 worth over $567,360. On average, Dr trades about 12,358 units every 163 days since 2020. As of 4 January 2024 he still owns at least 198,497 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Dr San stock trades at the bottom of the page.
Dr. Javier San Martin is the Chief Medical Officer at Arrowhead Pharmaceuticals.
As the Chief Medical Officer of Arrowhead Pharmaceuticals, the total compensation of Dr Martin at Arrowhead Pharmaceuticals is $673,571. There are 5 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of $2,216,260.
Dr Martin is 55, he's been the Chief Medical Officer of Arrowhead Pharmaceuticals since . There are 9 older and 7 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.
Martin's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone és Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: